NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT ), CDK Global, Inc. (NASDAQ: CDK ), Dynavax Technologies Corporation (NASDAQ: DVAX ), ICU Medical, Inc. (NASDAQ: ICUI ), American Vanguard Corporation (NYSE: AVD ), and Cabot Corporation (NYSE: CBT ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CORT DOWNLOAD: http://Fundamental-Markets.com/register/?so=CORT CDK DOWNLOAD: http://Fundamental-Markets.com/register/?so=CDK DVAX DOWNLOAD: http://Fundamental-Markets.com/register/?so=DVAX ICUI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ICUI AVD DOWNLOAD: http://Fundamental-Markets.com/register/?so=AVD CBT DOWNLOAD: http://Fundamental-Markets.com/register/?so=CBT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Corcept Therapeutics Incorporated (NASDAQ: CORT ), CDK Global, Inc. (NASDAQ: CDK ), Dynavax Technologies Corporation (NASDAQ: DVAX ), ICU Medical, Inc. (NASDAQ: ICUI ), American Vanguard Corporation (NYSE: AVD ), and Cabot Corporation (NYSE: CBT ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 7th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CORCEPT THERAPEUTICS INCORPORATED (CORT) REPORT OVERVIEW

Corcept Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Corcept Therapeutics reported revenue of $64.45MM vs $42.76MM (up 50.70%) and analysts estimated basic earnings per share $0.15 vs $0.12 (up 25.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Corcept Therapeutics reported revenue of $159.20MM vs $81.32MM (up 95.77%) and analysts estimated basic earnings per share $1.14 vs $0.07 (up 1,528.57%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The estimated EPS forecast for the next fiscal year is $0.81 and is expected to report on February 28th, 2019.

To read the full Corcept Therapeutics Incorporated (CORT) report, download it here: http://Fundamental-Markets.com/register/?so=CORT

-----------------------------------------

CDK GLOBAL, INC. (CDK) REPORT OVERVIEW

CDK Global's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, CDK Global reported revenue of $590.40MM vs $561.70MM (up 5.11%) and analysts estimated basic earnings per share $0.70 vs $0.76 (down 7.89%). For the twelve months ended June 30th, 2018 vs June 30th, 2017, CDK Global reported revenue of $2,273.20MM vs $2,220.20MM (up 2.39%) and analysts estimated basic earnings per share $2.80 vs $2.01 (up 39.30%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is $4.13 and is expected to report on August 13th, 2019.

To read the full CDK Global, Inc. (CDK) report, download it here: http://Fundamental-Markets.com/register/?so=CDK

-----------------------------------------

DYNAVAX TECHNOLOGIES CORPORATION (DVAX) REPORT OVERVIEW

Dynavax Technologies' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Dynavax Technologies reported revenue of $1.46MM vs $0.05MM (up 2,656.60%) and analysts estimated basic earnings per share -$0.65 vs -$0.38. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Dynavax Technologies reported revenue of $0.33MM vs $11.04MM (down 97.04%) and analysts estimated basic earnings per share -$1.81 vs -$2.92. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.43. The estimated EPS forecast for the next fiscal year is -$1.79 and is expected to report on March 14th, 2019.

To read the full Dynavax Technologies Corporation (DVAX) report, download it here: http://Fundamental-Markets.com/register/?so=DVAX

-----------------------------------------

ICU MEDICAL, INC. (ICUI) REPORT OVERVIEW

ICU Medical's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, ICU Medical reported revenue of $327.17MM vs $343.24MM (down 4.68%) and basic earnings per share $0.01 vs $0.01 (unchanged). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ICU Medical reported revenue of $1,292.61MM vs $379.37MM (up 240.72%) and analysts estimated basic earnings per share $3.50 vs $3.90 (down 10.26%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $2.70. The estimated EPS forecast for the next fiscal year is $8.54 and is expected to report on March 7th, 2019.

To read the full ICU Medical, Inc. (ICUI) report, download it here: http://Fundamental-Markets.com/register/?so=ICUI

-----------------------------------------

AMERICAN VANGUARD CORPORATION (AVD) REPORT OVERVIEW

American Vanguard's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, American Vanguard reported revenue of $111.78MM vs $89.98MM (up 24.23%) and analysts estimated basic earnings per share $0.22 vs $0.14 (up 57.14%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, American Vanguard reported revenue of $355.05MM vs $312.11MM (up 13.76%) and analysts estimated basic earnings per share $0.70 vs $0.44 (up 59.09%). Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The estimated EPS forecast for the next fiscal year is $0.88 and is expected to report on March 11th, 2019.

To read the full American Vanguard Corporation (AVD) report, download it here: http://Fundamental-Markets.com/register/?so=AVD

-----------------------------------------

CABOT CORPORATION (CBT) REPORT OVERVIEW

Cabot's Recent Financial Performance

For the twelve months ended September 30th, 2018 vs September 30th, 2017, Cabot reported revenue of $3,242.00MM vs $2,717.00MM (up 19.32%) and analysts estimated basic earnings per share -$1.85 vs $3.94. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.04. The estimated EPS forecast for the next fiscal year is $4.93 and is expected to report on November 4th, 2019.

To read the full Cabot Corporation (CBT) report, download it here: http://Fundamental-Markets.com/register/?so=CBT

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.